表紙
市場調査レポート

世界のジェネリック抗がん剤市場の見通し

Global Cancer Generics Market Outlook 2018

発行 RNCOS E-Services Pvt. Ltd. 商品コード 310599
出版日 ページ情報 英文 100 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
世界のジェネリック抗がん剤市場の見通し Global Cancer Generics Market Outlook 2018
出版日: 2014年08月01日 ページ情報: 英文 100 Pages
概要

世界のがん治療薬市場は、2013年に910億米ドルに達し、今後5年間のCAGRで約6%の成長を遂げると予測されています。一方、がん治療におけるジェネリック医薬品(ジェネリック抗がん剤)市場は、2018年には210億米ドルに達し、12%の成長が期待されています。

当レポートでは、世界のジェネリック抗がん剤市場について調査分析し、市場の現状と見通し、セグメント別の医薬品動向、主要企業プロファイルなどを含めて、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 世界のがん治療薬市場の見通し

  • がんの発生率
  • 抗がん剤市場

第4章 世界のジェネリック抗がん剤市場の分析

第5章 ジェネリック抗がん剤産業

  • 経口ジェネリック医薬品
    • Arimidex (Anastrozole)
    • Femara (Letrozole)
    • Hycamtin (Topotecan)
    • Stivarga (Regorafenib)
    • Tarceva (Erlotinib)
    • Xalkori (Crizotinib)
    • Xeloda (Capecitabine)
  • 注入ジェネリック医薬品
    • Camptosar (Irinotecan Hydrochloride)
    • Eloxatin (Oxaliplatin)
    • Gemzar (Gemcitabine Hydrochloride)
    • Navelbine (Vinorelbine Tartrate)
    • Platinol (Cisplatin)
    • Taxol (Paclitaxel)
    • Taxotere (Docetaxel)

第6章 ジェネリック抗がん剤市場:主な適応症

  • 肺がん
  • 乳がん
  • 大腸がん
  • 胃がん
  • 前立腺がん

第7章 市場動向

  • 米国市場に紹介されたインドのジェネリック抗がん剤
  • がん治療におけるジェネリック医薬品の発売
  • がん負担の増加がジェネリックの道を開く
  • がん治療におけるブロックバスター薬の特許期限切れ
  • 戦略的提携

第8章 主要企業

  • 事業概要、財務状況、戦略的発展など
    • Fresenius Kabi AG
    • Actavis Plc.
    • Hospira
    • Teva Pharmaceutical Industries Ltd.
    • Mylan
    • Sun Pharmaceuticals

図表

目次

With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such market is the oncology market. With global cancer incidences rising to almost 14.1 Million in 2012 and several blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience skyrocketing growth.

According to our latest research report "Global Cancer Generics Market Outlook 2018", the global oncology market touched a mark of US$ 91 Billion in 2013 and is poised to grow at a CAGR of approximately 6% over the next 5 year period. On the other hand, the market for cancer generics is expected to grow at 12%, reaching US$ 21 Billion by 2018. Patent expiry, low cost, and better life expectancy would be the major boosting factors for the cancer generics industry.

Our report essentially elicits the cancer industry under 2 heads viz. global oncology market and global caner generics market. Hereunder, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to major indications is also discussed in depth, with emphasis on current and future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.

Apart from the above mentioned study parameters the dossier also contains an analysis of the top notch global cancer generics manufacturers. On a holistic basis, the report is primarily inclined towards an in-depth study of the global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Cancer Drugs Market Outlook 2018

  • 3.1 Cancer Incidences
  • 3.2 Cancer Drug Market

4. Global Cancer Generics Market Analysis 2018

5. Cancer Generic Drugs Industry

  • 5.1 Oral Generic Drugs
    • 5.1.1 Arimidex (Anastrozole)
    • 5.1.2 Femara (Letrozole)
    • 5.1.3 Hycamtin (Topotecan)
    • 5.1.4 Stivarga (Regorafenib)
    • 5.1.5 Tarceva (Erlotinib)
    • 5.1.6 Xalkori (Crizotinib)
    • 5.1.7 Xeloda (Capecitabine)
  • 5.2 Generic Injectables
    • 5.2.1 Camptosar (Irinotecan Hydrochloride)
    • 5.2.2 Eloxatin (Oxaliplatin)
    • 5.2.3 Gemzar (Gemcitabine Hydrochloride)
    • 5.2.4 Navelbine (Vinorelbine Tartrate)
    • 5.2.5 Platinol (Cisplatin)
    • 5.2.6 Taxol (Paclitaxel)
    • 5.2.7 Taxotere (Docetaxel)

6. Cancer Generics Market: Major Indications

  • 6.1 Lung Cancer
    • 6.1.1 Incidence Outlook
    • 6.1.2 Commercialized Drugs
  • 6.2 Breast Cancer
    • 6.2.1 Incidence Outlook
    • 6.2.2 Commercialized Drugs
  • 6.3 Colorectal Cancer
    • 6.3.1 Incidence Outlook
    • 6.3.2 Commercialized Drugs
  • 6.4 Stomach Cancer
    • 6.4.1 Incidence Outlook
    • 6.4.2 Commercialized Drugs
  • 6.5 Prostate Cancer
    • 6.5.1 Incidence Outlook
    • 6.5.2 Commercialized Drugs

7. Market Dynamics

  • 7.1 Indian Generic Cancer Drug Introduced in the US Market
  • 7.2 Launch of Generic Drugs for Oncology
  • 7.3 Increasing Cancer Burden Paving Way for Generics
  • 7.4 Patent Expiry of Blockbuster Oncology Drugs
  • 7.5 Strategic Collaborations

8. Key Players

  • 8.1 Fresenius Kabi AG
    • 8.1.1 Business Overview
    • 8.1.2 Key Financials
    • 8.1.3 Strategic Developments
  • 8.2 Actavis Plc.
    • 8.2.1 Business Overview
    • 8.2.2 Key Financials
    • 8.2.3 Strategic Developments
  • 8.3 Hospira
    • 8.3.1 Business Overview
    • 8.3.2 Key Financials
    • 8.3.3 Strategic Developments
  • 8.4 Teva Pharmaceutical Industries Ltd.
    • 8.4.1 Business Overview
    • 8.4.2 Key Financials
    • 8.4.3 Strategic Developments
  • 8.5 Mylan
    • 8.5.1 Business Overview
    • 8.5.2 Key Financials
    • 8.5.3 Strategic Developments
  • 8.6 Sun Pharmaceuticals
    • 8.6.1 Business Overview
    • 8.6.2 Key Financials
    • 8.6.3 Strategic Developments

List of Figures:

  • Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2025
  • Figure 3-2: Global - Cancer Incidences by Gender (Million), 2012
  • Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2008-2013
  • Figure 3-4: Global - Cancer Drugs Market (Billion US$), 2014-2018
  • Figure 3-5: Cancer Drugs Market Share by Geography (%), 2013
  • Figure 3-6: Cancer Drugs Market Share by Geography (%), 2018
  • Figure 3-7: Global - Cancer Treatment Modalities Revenue Share (%), 2013
  • Figure 4-1: Global - Cancer Generics Market (Billion US$), 2013-2018
  • Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2012 & 2020
  • Figure 6-2: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
  • Figure 6-3: Global - Number of New Breast Cancer Cases (Million), 2012 & 2020
  • Figure 6-4: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
  • Figure 6-5: Global - Number of New Colorectal Cancer Cases (Million), 2012 & 2020
  • Figure 6-6: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
  • Figure 6-7: Global - Number of New Stomach Cancer Cases (Million), 2012 & 2020
  • Figure 6-8: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
  • Figure 6-9: Global - Number of New Prostate Cancer Cases (Million), 2012 & 2020
  • Figure 6-10: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
  • Figure 8-1: Fresenius Kabi - Sales & Net Income (Billion US$), 2012 & 2013
  • Figure 8-2: Fresenius Kabi - Revenue Share by Region (%), 2013
  • Figure 8-3: Fresenius Kabi - Revenue Share by Business Segment (%), 2013
  • Figure 8-4: Actavis - Sales & Net Income (Billion US$), 2012 & 2013
  • Figure 8-5: Actavis - Revenue Share by Region (%), 2013
  • Figure 8-6: Actavis - Revenue Share by Business Segment (%), 2013
  • Figure 8-7: Hospira - Sales & Net Income (Billion US$), 2012 & 2013
  • Figure 8-8: Hospira - Revenue Share by Region (%), 2013
  • Figure 8-9: Hospira - Revenue Share by Business Segment (%), 2013
  • Figure 8-10: Teva - Sales & Net Income (Billion US$), 2012 & 2013
  • Figure 8-11: Teva - Revenue Share by Region (%), 2013
  • Figure 8-12: Hospira - Revenue Share by Business Segment (%), 2013
  • Figure 8-13: Mylan - Sales & Net Income (Billion US$), 2012 & 2013
  • Figure 8-14: Mylan - Revenue Share by Region (%), 2013
  • Figure 8-15: Mylan - Revenue Share by Business Segment (%), 2013
  • Figure 8-16: Sun Pharma - Sales & Net Income (Billion US$), 2012-13/ 2013-14
  • Figure 8-17: Sun Pharma - Revenue Share by Business Segment (%), 2013-14

List of Tables:

  • Table 3-1: Most Prevalent Types of Cancer
  • Table 3-2: Top 10 Countries with Highest Cancer Prevalence Rates
  • Table 5-1: List of Companies Dealing in Generic Arimidex
  • Table 5-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
  • Table 5-3: List of Companies Dealing in Generic Femara
  • Table 5-4: Cost Comparison of Generics and Branded Femara (Letrozole)
  • Table 5-5: List of Companies Dealing in Generic Hycamtin
  • Table 5-6: List of Companies Dealing in Generic Xeloda
  • Table 5-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
  • Table 5-8: List of Companies Dealing in Generic Camptosar
  • Table 5-9: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
  • Table 5-10: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
  • Table 5-11: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
  • Table 5-12: List of Companies Dealing in Generic Navelbine (Vinorelbine)
  • Table 5-13: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
  • Table 5-14: List of Companies Dealing in Generic Platinol (Cisplatin)
  • Table 5-15: List of Companies Dealing in Generic Taxol (Paclitaxel)
  • Table 5-16: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
  • Table 5-17: List of Companies Dealing in Generic Taxotere (Docetaxel)
  • Table 5-18: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
  • Table 6-1: Top 10 Countries by Lung Cancer Incidences (2012)
  • Table 6-2: Global - Key Lung Cancer Drugs and Patent Expiry Status
  • Table 6-3: Top 10 Countries by Breast Cancer Incidences (2012)
  • Table 6-4: Global - Key Breast Cancer Drugs and Patent Expiry Status
  • Table 6-5: Top 10 Countries by Colorectal Cancer Incidences (2012)
  • Table 6-6: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
  • Table 6-7: Top 10 Countries by Stomach Cancer Incidences (2012)
  • Table 6-8: Global - Key Stomach Cancer Drugs and Patent Expiry Status
  • Table 6-9: Top 10 Countries by Prostate Cancer Incidences (2012)
  • Table 6-10: Global - Key Prostate Cancer Drugs and Patent Expiry Status
  • Table 7-1: Global - Key Cancer Drugs and Patent Expiry Status
  • Table 8-1: Fresnius Kabi Pharmaceuticals - Key Cancer Generic Drugs
  • Table 8-2: Actavis - Key Cancer Generic Drugs
  • Table 8-3: Hospira - Key Cancer Generic Products
  • Table 8-4: Teva Pharmaceuticals - Key Cancer Generic Drugs
  • Table 8-5: Mylan - Key Cancer Generic Drugs
  • Table 8-6: Sun Pharmaceuticals - Key Cancer Generic Drugs
Back to Top